Opening paths to the global healthcare markets

Over twenty years’ experience in the commercialisation of Biotech and Medtech innovations in the USA, Europe and Australia.

About

Med2Mark

Commercial Expertise: We provide expert advice on the commercialisation of biotech and MedTech innovations, beyond the Regulatory Clearances, i.e. Health Economics, Reimbursement, Distribution and most importantly Adoption. Med2Mark thoroughly assesses the commercial value of Health-Tech innovations before significant investments are committed. We are selective and engage, for the long run, in projects with strong commercialisation and actual adoption potentials.

Global Experience: We are an international boutique Consulting Practice with over twenty years’ experience in the commercialisation of Biotech and Medtech innovations in the USA, Europe and Australia. We are available to directly support the management team, as illustrated by David’s Executive positions in Philia Labs, Attilio’s CEO position in Verum Diagnostics, as well as Pierre’s CEO position in Jay-Nik, three startups we came across through our consulting activities.

How we help you commercialise

your health-tech innovations

HEALTH ECONOMICS & HEALTH IMPACT ASSESSMENT

Definition of Health Impact Strategies: Assessment of the heathcare system’s capacity to maximise the potential benefits of your innovation at the delivery point.

Substantiation of Health Economics value to build Reimbursement dossiers: Clinical and economic...

GO-TO-MARKET STRATEGY


Market Access Strategy: We map out the regulatory pathways and reimbursement options applicable to your innovation.

Markets Assessment & Financial Modelling: From the Global Market to the Total Addressable Market, we provide you with actionable information...

COMMERCIALISATION & ADOPTION


KOLs Engagement & early adoption: Engagement of subject experts and Key Opinion Leaders to accelerate early adoption of your innovation.

FINANCIAL ANALYSIS & VALUATION


Validate the financial projections to support fundraising activities and exit negotiations.

Advice to Investors based on expected commercial returns: We translate the complexities of healthtech commercialisation into a succinct dashboard...

Our International experts

Team

Med2Mark

Created in 2017, Med2Mark is a boutique Consulting Practice built around seven Associates, each with over twenty years’ experience in the translation of Biotech and Medtech innovations. Our clients are located in the USA, Europe, China and Australia.


Together, in the last 2 years, we have helped bring 2 BioTech, 1 MedTech and 6 IVD products to the market.

7

Experts

Across the USA, Europe, Asia and Australia.

20+

Years

Experience in Biotech & Medtech.

7

Experts

Across the USA, Europe, Asia and Australia.

20+

Years

Experience in Biotech & Medtech.

Pierre Nathie
Managing Director
Melbourne, Australia

Read more

Michael Wienholt
Managing Partner
NC, USA

Read more

Louise Creswell
Managing Partner
Worcestershire, UK

Read more

Attilio Baldassi
Managing Partner
Atlanta, USA

Read more

Wei Huang
Managing Partner
Shanghai, China

Read more

David Lester
Managing Partner
Melbourne, Australia

Read more

Wolfgang Hofgaertner
Managing Partner
NJ, USA

Read more

CASE STUDY

1

Commercial strategy for phase II NIH grant

BioTech

Our Client: US-based Biotech start-up commercialising a range of patented natural source products for the oral health and anti-viral consumer and therapeutics market.

What we did: Researched and detailed the overall value of the proposed program and its expected outcomes with an accompanying market opportunity analysis, summary finance plan, and market channel approaches.

Our results: Phase II grant successfully funded with a high score for the commercial strategy section.

CASE STUDY

2

Define company’s go-to-market strategy

MedTech

Our Client: Australia-based MedTech start-up.

What we did: Strategic analysis of the market (Porter) resulting in recommendation to consolidate IP and exit early.

Our results: Recommendation accepted and backed up by private investors.

CASE STUDY

3

Secure reimbursement in Europe

IVD

Our Client: Singapore-based BioTech start-up commercialising 3D cell-based test that mimics patients’ response to cytostatic drugs.

What we did: A comprehensive Health Technology Assessment centred on Health Economics evidence (ICER).

Our results: Test reimbursed by the two targeted German private health insurance companies.

CASE STUDY

4

Achieve certification to ISO 13485

IVD

Our Client: US-based contract manufacturer of lateral flow devices.

What we did: Process map, draft SOPs, WIs, Forms and Templates, guide.

Our results: Achieved certification to ISO 13485 within 8 months.

Our Clients

We advise health innovators located in Europe, the US and Australia.

Contact us

We help you turn your health-tech innovations into commercial successes.